Goldman Sachs
NVCT icon

Goldman Sachs’s Nuvectis Pharma NVCT Stock Holding History

Goldman Sachs’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Sell
20,480
-20,644
-50% -$231K ﹤0.01% 5875
2026
Q1 		$318K Buy
41,124
+14,621
+55% +$125K ﹤0.01% 5868
2025
Q4 		$200K Sell
26,503
-18,660
-41% -$122K ﹤0.01% 6043
2025
Q3 		$272K Buy
+45,163
New +$310K ﹤0.01% 5809
2025
Q2 		– Sell
-45,608
Closed -$446K – 6321
2025
Q1 		$446K Buy
+45,608
New +$328K ﹤0.01% 5253
2024
Q3 		– Sell
-61,570
Closed -$390K – 5999
2024
Q2 		$390K Buy
+61,570
New +$418K ﹤0.01% 4963

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Goldman Sachs's NVCT Position: Q2 2026 in Review

Goldman Sachs reduced its Nuvectis Pharma (NVCT) stake by 50% in Q2 2026, selling an estimated $231K and leaving 20,480 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #5875.

Goldman Sachs first reported a position in NVCT in Q2 2024 and has held it in 6 quarters since. The position peaked at $446K in Q1 2025. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Goldman Sachs held 20,480 shares of Nuvectis Pharma worth $377K as of Q2 2026.
  • Goldman Sachs sold 20,644 Nuvectis Pharma shares in Q2 2026, an estimated $231K.
  • Nuvectis Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5875 holding.
  • Goldman Sachs first reported a position in Nuvectis Pharma in Q2 2024 and has held it in 6 quarters since.
  • Goldman Sachs's Nuvectis Pharma position peaked at $446K in Q1 2025.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.